Article Text

Download PDFPDF
Research paper
Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort
  1. Arya Shah1,
  2. E Matthew Hoffman1,
  3. Michelle L Mauermann1,
  4. Charles L Loprinzi2,
  5. Anthony J Windebank1,
  6. Christopher J Klein1,
  7. Nathan P Staff1
  1. 1 Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Nathan P Staff, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA; staff.nathan{at}


Objective To assess disease burden of chemotherapy-induced peripheral neuropathy (CIPN), which is a common dose-limiting side effect of neurotoxic chemotherapy. Late effects of CIPN may increase with improved cancer survival.

Methods Olmsted County, Minnesota residents receiving neurotoxic chemotherapy were identified and CIPN was ascertained via text searches of polyneuropathy symptoms in the medical record. Clinical records were queried to collect data on baseline characteristics, risk factors, signs and symptoms of CIPN, medications, impairments and International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes for all subjects.

Results A total of 509 individuals with incident exposure to an inclusive list of neurotoxic chemotherapy agents between 2006 and 2008 were identified. 268 (52.7%) of these individuals were determined to have CIPN. The median time from incident exposure to first documented symptoms was 71 days. Patients with CIPN received a neuropathy ICD-9 diagnosis in only 37 instances (13.8%). Pain symptoms and use of pain medications were observed more often in patients with CIPN. Five-year survival was greater in those with CIPN (55.2%) versus those without (36.1%). Those with CIPN surviving greater than 5 years (n=145) continued to have substantial impairments and were more likely to be prescribed opioids than those without CIPN (OR 2.0, 1.06–3.69).

Conclusions Results from our population-based study are consistent with previous reports of high incidence of CIPN in the first 2 years following incident exposure to neurotoxic chemotherapeutic agents, and its association with significant pain symptomatology and accompanied long-term opioid use. Increased survival following exposure to neurotoxic chemotherapy and its long-term disease burden necessitates further study among survivors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Study concept and design: AS, EMH, NPS. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: AS, EMH, NPS. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: AS, EMH, NPS. Obtained funding: NPS. Study supervision: NPS.

  • Funding The study was supported by the Mayo Foundation for Medical Education and Research, Rochester Epidemiology Project and National Institutes of Health: K08 CA169443 (NPS), R01 CA 211887 (NPS), R01 AG034676 (Rochester Epidemiology Project), UL1 RR000135 (Clinical and Translational Sciences Award).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval The Institutional Review Boards of both Mayo Clinic and Olmsted Medical Center approved this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles